Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

Metagenomic method for in vitro diagnosis of gut dysbiosis

DysbiosisEating disordersGut diseasesMicrobiomeobesity

Introduction

Bambino Gesù Children Hospital’s researchers have developed the first method for an accurate in vitro diagnosis of gut microbiota alterations (dysbiosis), providing a precious and low cost tool for a personalized therapeutic approach to very common gastrointestinal and gastrointestinal-related diseases.

Technical features

Gut Microbiota is a community of microorganisms living in the human gut, with protective and metabolic functions. Its alteration is very frequent and related to very common gastrointestinal diseases. Effective intervention needs a personalized therapeutic approach based on an accurate quantitative diagnosis of the patient’s dysbiosis. There is currently no effective method available for such quantitative diagnosis. This innovative method is based on 2nd generation NGS (next generation sequencing) technology applied to targeted-metagenomics sequencing, provides an accurate measurement of the degree of dysbiosis.

Possible Applications

  • Eating disorders and obesity;
  • Inflammatory bowel diseases;
  • Type I and II diabetes;
  • Cystic Fibrosis;
  • Autoimmune diseases;
  • Steatosis/ hepatic fibrosis;
  • Autism;
  • Malignancies.

Advantages

  • It provides a precise and measurable diagnosis of gut disbyosis, for a personalized therapeutic approach;
  • It is an accurate and low-cost solution for a widely recognized clinical needs both in children and in adults;
  • It is applicable to over 50% of population.